These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 12176616

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD.
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
    Woodside KJ, Lick SD.
    J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
    [Abstract] [Full Text] [Related]

  • 8. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'alessandro AM, Sollinger HW.
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [Abstract] [Full Text] [Related]

  • 11. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B, Shoemaker L, Recto M, Austin E, Dowling R.
    J Heart Lung Transplant; 2008 Feb; 27(2):242-4. PubMed ID: 18267235
    [Abstract] [Full Text] [Related]

  • 12. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P, Zilvetti M, Friend P, Wood KJ.
    Transplantation; 2006 Nov 27; 82(10):1342-51. PubMed ID: 17130784
    [Abstract] [Full Text] [Related]

  • 13. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep 27; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM, Haidinger M, Zeyda M, Böhmig GA, Tombinsky J, Mühlbacher F, Watschinger B, Hörl WH, Säemann MD.
    Transpl Immunol; 2006 Nov 27; 16(3-4):254-7. PubMed ID: 17138063
    [Abstract] [Full Text] [Related]

  • 15. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
    Reams BD, Davis RD, Curl J, Palmer SM.
    Transplantation; 2002 Sep 27; 74(6):903-4. PubMed ID: 12364881
    [No Abstract] [Full Text] [Related]

  • 16. Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
    Pinna AD, Weppler D, Nery JR, Khan F, Ruiz P, Kato T, De Faria W, Berho M, Tzakis AG.
    Transplant Proc; 2000 Sep 27; 32(6):1193-4. PubMed ID: 10995902
    [No Abstract] [Full Text] [Related]

  • 17. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.
    Transplantation; 2009 Oct 15; 88(7):904-10. PubMed ID: 19935462
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
    Clatworthy MR, Friend PJ, Calne RY, Rebello PR, Hale G, Waldmann H, Watson CJ.
    Transplantation; 2009 Apr 15; 87(7):1092-5. PubMed ID: 19352132
    [Abstract] [Full Text] [Related]

  • 19. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK.
    Transplantation; 2007 Jun 15; 83(11):1509-12. PubMed ID: 17565326
    [Abstract] [Full Text] [Related]

  • 20. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P, Madariaga JR, Kato T, Nishida S, Levi DM, Moon J, Selvaggi G, De Faria W, Regev A, Bejarano P, Khaled A, Safdar K, Esquenazi V, Weppler D, Yoshida H, Ruiz P, Miller J, Tzakis AG.
    Transplant Proc; 2005 Mar 15; 37(2):1203-4. PubMed ID: 15848669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.